Deka Bank Deutsche Girozentrale Inhibrx, Inc. Transaction History

Deka Bank Deutsche Girozentrale

  • $53.9 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 28, 2022
BUY
$19.89 - $43.18 $47,736 - $103,632
2,400 Added 10.0%
26,400 $590,000
Q4 2021

Feb 02, 2022
BUY
$26.75 - $46.02 $642,000 - $1.1 Million
24,000 New
24,000 $1.06 Million

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email